ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1378	National Cancer Institute	Html	en	Childhood Brain Stem Glioma Treatment (PDQ®)–Health Professional Version	Diffuse intrinsic pontine glioma (DIPG) is a fast-growing childhood brain stem glioma that is difficult to treat and has a poor prognosis. A focal glioma grows more slowly, is easier to treat, and has a better prognosis. Learn about the diagnosis, cellular classification, staging, treatment, and clinical trials for pediatric brain stem glioma in this expert-reviewed summary.	corresponding treatment summary 0.689411 focal brainstem gliomas 0.801159 brain stem tumours 0.666641 diffuse brainstem gliomas 0.915552 adult high-grade gliomas 0.779058 brain tumors 0.871609 children 0.712329 histologic confirmation 0.674199 pediatric high-grade gliomas 0.777704 diffuse intrinsic brain 0.79588 clinical trials 0.703298 Tumors Treatment Overview 0.783812 H3 K27M mutation 0.767013 phase I/II study 0.654843 Primary tumors 0.67784 high-risk brainstem tumors 0.802443 World Health Organization 0.800016 brain stem tumors 0.783084 single new treatment 0.675971 brainstem gliomas 0.982733 specific H3 K27M 0.672189 common solid tumor 0.66912 radiation therapy 0.772489 intrinsic pontine glioma 0.876111 diffuse pontine gliomas 0.849232	Diffuse brainstem glioma 0.837788 et al. 0.72856 intrinsic brainstem gliomas 0.920288 childhood cancer mortality 0.676419 intrinsic pontine gliomas 0.828567 Glioma Cooperative Group 0.697725 brain tumor treatment 0.735178 brain stem gliomas 0.821857 3-dimensional conformal radiation therapy 0.714672 low-grade morphological characteristics 0.653573 Pediatr Blood Cancer 0.768008 paediatric pontine glioma 0.728445 diffuse intrinsic brainstem 0.904976 Primary brain tumors 0.784905 Abstract 0.747074 pediatric brain tumors 0.745588 nervous system tumors 0.673857 H3 K27M mutation. 0.670015 Clin Oncol 0.65677 childhood brain tumors 0.756852 newly diagnosed diffuse 0.79983 pediatric diffuse 0.708327 thalamic tumors 0.673454 midline high-grade gliomas 0.786516	CLICK HERE
1509	National Cancer Institute	Html	en	Ovarian Low Malignant Potential Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors.	actuarial survival rate 0.630338 significantly higher incidence 0.497662 survival rates 0.647886 excellent survival rates 0.613575 ovarian cystic neoplasms 0.524669 large series 0.505974 advanced-stage tumors 0.534809 survival rate 0.991192 serous tumors 0.508069 aggressive cytoreductive surgery 0.508958 intraperitoneal disease 0.508061 gross residual tumor 0.624183 DNA ploidy 0.473971 presumed localized tumors 0.627355 primary serous tumor 0.543013 patients 0.874529 gross residual disease. 0.554008 small bowel obstruction 0.517717 20-year survival rates 0.623524 total abdominal hysterectomy 0.500134 malignant potential tumors 0.654434 epithelial ovarian cancers 0.560469 positive lymph nodes 0.513754 secondary cytoreductive procedure 0.496028 malignant invasive carcinomas 0.598953	Oncology Group study 0.492475 borderline ovarian tumors 0.602765 early-stage disease 0.53696 borderline tumors 0.543947 7-year survival rate 0.610698 aneuploid tumors 0.485651 low malignant potential 0.549837 gross residual disease 0.749508 tumor recurrence 0.473805 so-called invasive implants 0.548607 low malignant potential. 0.544407 invasive tumors 0.531513 negative lymph nodes 0.509204 radiation therapy alters 0.492888 borderline tumor 0.475678 d’Obstetrique Annual Report 0.515222 tumor reductive surgery 0.541448 aneuploid invasive implants 0.511492 invasive implants 0.72297 life table analysis 0.517429 tumors 0.678345 completely resected tumor 0.568634 residual tumor 0.843362 large prospective study. 0.509685	CLICK HERE
1595	National Cancer Institute	Html	en	Gastric Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of gastric cancer.	treatment 0.591238 cancer treatment 0.450405 gastric cancer cells 0.441573 Gastric Cancer Treatment 0.444726 NCI-supported cancer 0.4391 stomach 0.735063 cancer cells 0.582767 malignant tumor cells 0.419107 body 0.442061 Cancer Information Service 0.403362 PDQ cancer information 0.496418 specific cancer cells 0.40594 HER2-positive gastric cancer 0.441612 clinical trial search 0.508645 stomach wall 0.679257 treatment clinical trials 0.435225 National Cancer Institute 0.459181 clinical trials 0.857251 nearby lymph nodes 0.422969 cancer information summary 0.459638 clinical trial 0.69582 gastric cancer spreads 0.435883 new treatment 0.430993	gastric cancer 0.961916 recurrent gastric cancer 0.423214 ) layer. 0.427318 stomach disease 0.413534 patients 0.40139 metastatic gastric cancer 0.437702 Stomach pain 0.405557 NCI PDQ cancer 0.415126 cancer clinical trials 0.531962 lymph nodes 0.644979 stage 0.470953 stomach cancer 0.464876 tumor 0.483246 chemoradiation therapy 0.469475 radiation therapy 0.455319 Treatment Editorial Board 0.403905 cancer information summaries 0.401354 stomach discomfort 0.411852 information 0.507295 small intestine 0.476652 subtotal gastrectomy 0.452908 monoclonal antibody 0.404834 General information 0.405606	CLICK HERE
1753	National Cancer Institute	Html	en	Hormone Therapy for Breast Cancer	A fact sheet that describes types of hormone therapy, its role in preventing and treating breast cancer, and possible side effects.	Surgical Adjuvant Breast 0.492707 estrogen 0.502159 primary breast cancer 0.489122 early-stage ER-positive breast 0.480551 aromatase inhibitors anastrozole 0.480936 ER-positive early-stage breast 0.480383 aromatase inhibitors 0.525562 breast cancer subtypes 0.491642 metastatic ER-positive breast 0.481109 early-stage breast cancer 0.616245 tamoxifen 0.550216 breast cancer hormone 0.522198 ER-positive breast cancer 0.553345 breast cancer prevention 0.522495 breast cancer patients 0.511592 postmenopausal breast cancer 0.509489 new breast cancer 0.500245 adjuvant hormone therapy 0.504935 estrogen receptors 0.483294 HR-positive breast cancer 0.521679 hormone receptor-positive breast 0.501962 metastatic breast cancer 0.52726 invasive breast cancer 0.511911 early breast cancer 0.587772	breast cancer cells 0.575964 breast cancer recurrence 0.50934 breast cancers 0.514423 ER-positive breast cancers 0.488424 premenopausal women 0.499525 National Cancer Institute 0.500748 IBIS-I breast cancer 0.488534 hormone therapy 0.718328 hormone-sensitive breast cancer 0.587411 breast tumors 0.505842 postmenopausal women 0.702436 breast cancer risk 0.498557 International Breast Cancer 0.496186 Letrozole Breast Cancer 0.491109 estrogen receptor 0.488845 advanced hormone-sensitive breast 0.480069 receptor–positive breast cancer 0.52072 breast cancer 0.988243 Breast Cancer Trialists 0.51995 adjuvant tamoxifen 0.489054 tamoxifen treatment 0.48115 hormone receptor–positive breast 0.534822 et al 0.566786 advanced breast cancer 0.554835	CLICK HERE
1757	National Cancer Institute	Html	en	Biological Therapies for Cancer	A fact sheet that provides an overview of how the immune system functions and describes the actions of biological therapies.	red blood cells 0.577776 cancer vaccines 0.49997 certain cells 0.540439 human cells 0.554952 healthy cells 0.559468 immune responses 0.496164 dendritic cells 0.583067 white blood cells 0.751432 activated T cells 0.553284 Targeted Cancer Therapies 0.4932 clinical trials 0.665835 anticancer immune response 0.557063 reproductive cells 0.533783 cancer treatment vaccines 0.521084 stem cells 0.582774 biological therapies 0.676853 biological therapy 0.585141 gene therapy 0.624656 cancer cell surface 0.49085 metastatic breast cancer 0.502756 blood-forming stem cells 0.552734 dead cells 0.564287 oncolytic viruses 0.562901 oncolytic virus therapy 0.524139 breast cancer cells 0.605883	abnormal cells 0.587571 non-Hodgkin lymphoma cells 0.585453 receptor-modified T cells 0.533588 Severe allergic reaction 0.495224 cancer cells 0.939837 killer T cells 0.545739 tumour cells 0.53329 immune response 0.649552 antibody-producing cells 0.554007 blood stem cells 0.57668 tumor cells 0.642236 normal cells 0.598729 identical daughter cells 0.56732 immune cells 0.615338 bladder cancer cells 0.599791 laboratory-grown T cells 0.538366 natural killer cells 0.629042 cells 0.962945 cancer clinical trials 0.496931 cytotoxic t cells 0.651132 et al 0.571194 genetically modified cells 0.552195 hematopoietic stem cells 0.563457 immortal hybridoma cells 0.568993	CLICK HERE
1762	National Cancer Institute	Html	en	Access to Investigational Drugs	A fact sheet that defines investigational drugs (drugs under study but not yet FDA approved) and describes ways one might get access to these treatments.	NCI-designated cancer centers 0.38027 specific drug 0.365425 following criteria 0.380266 NCI program 0.360621 NCI’s Cancer 0.393319 case-by-case basis 0.385443 specific investigational drug 0.531382 FDA approval process 0.46336 NCI’s role 0.358363 TRC protocol 0.386712 Biologics License Application 0.383962 Institutional Review Board 0.372082 special exception programs 0.401115 investigational agent 0.482556 clinical trials 0.558265 specific criteria 0.382975 U.S. Food 0.350319 special exception mechanism 0.383615 clinical trial 0.636376 patients 0.498827 Special Exception/Compassionate Exemption 0.383931 access protocol 0.441767 drug development 0.379672 study sponsor 0.351362 Investigational New Drug 0.563996	FDA approval 0.502957 New Drug Application 0.4108 wide geographic availability 0.374872 NCI 0.425588 expanded access protocols 0.412645 IND 0.351277 investigational drug 0.866441 sponsor 0.450913 treatment 0.39466 access 0.446945 new drugs 0.396554 Drug Administration 0.379954 Cancer Information Service 0.448715 special exception 0.541023 compassionate exception 0.351227 investigational drugs 0.95169 patient 0.385651 appropriate reviewing division 0.371824 drug company 0.56293 expanded access protocol 0.400476 health insurance company 0.376702 CIS information specialists 0.382598 clinical trials database 0.391459 Treatment Referral Center 0.38112	CLICK HERE
1937	National Cancer Institute	Html	es	Tratamiento de los cánceres poco comunes en la niñez (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los cánceres poco comunes en la niñez como los cánceres de la cabeza y el cuello, el tórax, el abdomen, el aparato reproductor, la piel y otros.	glándula tiroides 0.938162 siguientes procedimientos 0.472657 posibles efectos tardíos 0.3766 hormona tiroidea 0.437118 color blanco plateado 0.323284 adultos jóvenes 0.322007 efectos secundarios meses 0.525317 faja ajustadora 0.360779 pequeña cantidad 0.416767 tratamiento causa 0.422854 células normales.ampliar exploración 0.550413 ecografía completa 0.326705 vía oral 0.351058 rayos x 0.35409 Masas indoloras 0.337566 niño ayuda 0.375685 efectos tardíos 0.809559 escáner.ampliar exploración 0.389789 PDQ Efectos tardíos 0.373896 vías respiratorias 0.465531	tarde.ampliar ecografía 0.364218 órgano fonador 0.316018 tumores benignos 0.352678 gen apc 0.327747 endocrina múltiple tipo 0.438625 PDQ Tratamiento 0.416786 área pequeña detrás 0.333456 gen nut 0.365005 siguientes problemas 0.361501 explorador tep 0.372891 siguientes signos 0.678578 nuevos tipos 0.336277 gen pten 0.328711 enfermedad.ampliar endoscopia 0.360667 linfocitos t 0.350025 hormona calcitonina 0.330174 células tiroideas 0.433364 toma imágenes 0.349043 Ojos saltones 0.331931	CLICK HERE
3598	National Cancer Institute	Html	en	Childhood Cancer Survivor Study: An Overview	Health problems that develop years later as a result of a cancer treatment are known as late effects. The Childhood Cancer Survivor Study (CCSS) was started in 1994 to better understand these late effects.	Cancer Survivor Study 0.651761 Clinical Oncology 0.430017 childhood cancer 0.933179	journal article 0.545579 childhood cancer survivor 0.797555	CLICK HERE
14596	National Cancer Institute	Html	en	What Is Cancer?	Explanations about what cancer is, how cancer cells differ from normal cells, and genetic changes that cause cancer to grow and spread.	benign brain tumors 0.40676 star-shaped brain cells 0.473891 human cells 0.482443 nearby normal cells 0.498609 squamous cells 0.495031 body’s cells 0.493774 tumor suppressor genes 0.441927 white blood cells 0.5174 malignant tumors 0.410135 Reed-Sternberg cells 0.446673 abnormal plasma cells 0.47073 tissues 0.391204 epithelial cell types 0.372838 extra cells 0.532701 blood vessels 0.389179 nerve cells 0.450383 solid tumors 0.421449 DNA repair genes 0.397134 Metastatic tumors 0.385874 carcinoid tumors 0.394635 metastatic breast cancer 0.390046 cancers 0.429846 immune system cells 0.472603 myeloma cells 0.447313 soft tissue sarcoma 0.382156	neuroendocrine tumors 0.396625 different cells 0.465518 abnormal cells 0.497795 metastatic cancer cells 0.542261 cancer cells 0.711115 normal blood cells 0.520987 unneeded cells 0.469669 new cells 0.509463 squamous cell 0.373428 normal cells 0.564574 types 0.419663 epithelial cells 0.524359 Cancerous tumors 0.382835 genetic changes 0.400724 tumors 0.551639 germ cell tumors 0.421823 cells 0.91549 new tumors 0.381387 benign tumors 0.426682 damaged cells 0.483579 cells function 0.467145 cancer 0.716841 leukemia cells 0.447258 spinal cord tumors 0.44102	CLICK HERE
15653	National Cancer Institute	Html	en	Grant Closeout	Learn about the administrative actions and requirements to comply with grants closeout.	recipient institution 0.403385 current competitive segment 0.4584 Final Research Performance 0.470424 FRPPR 0.272101 Progress Report 0.292765 recipient organization 0.397988 business official 0.281485 Report Additional Materials 0.646337 new competitive segment 0.466064 Interim RPPR 0.480283 Final RPPR 0.617886 Guide Notice 0.494667 applicable administrative actions 0.459328 project period 0.315182 Process Final RPPR 0.451009 Closeout status screen 0.633167 federal government 0.280609 eRA Commons 0.988859 Final Report Additional 0.435922 additional information 0.556844 Guide Notice NOT-OD-17-037 0.449856	future funding 0.297581 Interim Report Additional 0.450898 IRPPR link 0.291974 IRPPR 0.302645 property accountability 0.290412 later refunds 0.280936 competitive segment 0.500951 grant closeout process 0.873148 closeout documentation 0.730869 current annual RPPR 0.439246 financial accountability 0.290106 Unilateral Closeout action 0.746529 Signing Official 0.282197 grant support 0.576328 additional information online 0.441695 record retention 0.281581 renewal application 0.63575 new institution 0.307358 program directors 0.303803 grant closeout reports 0.857404 submission 0.258668	CLICK HERE